879 related articles for article (PubMed ID: 23792295)
1. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
Drobne D; Bossuyt P; Breynaert C; Cattaert T; Vande Casteele N; Compernolle G; Jürgens M; Ferrante M; Ballet V; Wollants WJ; Cleynen I; Van Steen K; Gils A; Rutgeerts P; Vermeire S; Van Assche G
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):514-521.e4. PubMed ID: 25066841
[TBL] [Abstract][Full Text] [Related]
3. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
4. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.
Waters H; Vanderpoel J; McKenzie S; Lunacsek O; Franklin M; Lennert B; Goff J; Augustyn DH
J Med Econ; 2011; 14(4):397-402. PubMed ID: 21595522
[TBL] [Abstract][Full Text] [Related]
5. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.
Mandel MD; Balint A; Golovics PA; Vegh Z; Mohas A; Szilagyi B; Szabo A; Kurti Z; Kiss LS; Lovasz BD; Gecse KB; Farkas K; Molnar T; Lakatos PL
Dig Liver Dis; 2014 Nov; 46(11):985-90. PubMed ID: 25156871
[TBL] [Abstract][Full Text] [Related]
6. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
9. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity.
Niewiadomski O; Studd C; Hair C; Wilson J; Ding NS; Heerasing N; Ting A; McNeill J; Knight R; Santamaria J; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Popp B; Connell W; Desmond P; Bell S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1346-53. PubMed ID: 25867770
[TBL] [Abstract][Full Text] [Related]
10. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
11. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
Ben-Horin S; Waterman M; Kopylov U; Yavzori M; Picard O; Fudim E; Awadie H; Weiss B; Chowers Y
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):444-7. PubMed ID: 23103905
[TBL] [Abstract][Full Text] [Related]
12. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
13. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
14. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
15. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
16. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
Baert F; Drobne D; Gils A; Vande Casteele N; Hauenstein S; Singh S; Lockton S; Rutgeerts P; Vermeire S
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.
Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D
Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
19. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
[TBL] [Abstract][Full Text] [Related]
20. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
